Good Morning #GImedTwitter

🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)

🧑‍🏫Get ready for 3 packed days of presentations at #GI22

And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯


Once again HER2🎯💊is everywhere #GI22

👉The DESTINY trials have been👍4⃣T-DXd

➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD
#TumorBoardTuesday #GI22

✅DESTINY-Gastric 01
➡️K Yamaguchi, et al "RAPID" Abs 242
⏩Randomized Ph II trial of >=2nd line💊
👉T-DXd vs. Physician’s choice (PC) which was Iri or Paclitaxel
⏩mOS 12.5 v 8.9 mos
⏩ORR 51% vs 14%
😨But Grade >= 3 AEs were 86% vs 57%
#TumorBoardTuesday #GI22

🧑‍🏫Also take a look at:
@YJanjigianMD , et al Abs 295

✅N Li, et al, Abs 296
➡️SHR1210 (anti-PD-1) ➕trastuzumab➕CAPEOX 👉As NEOADJUVANT💊for HER2+ GC/GEJ
⏩31% path CR rate

🧑‍🏫Remember Pembro➕Tras➕CAPEOX
➡️75% ORR in KN-811
#TumorBoardTuesday #GI22

There were a few “me too” anti-PD-1 MSI-high trials

✅But the GERCOR NEONIPIGA trial stood out to me
➡️T Andre, et al "RAPID"Abs 244
⏩Neoadj Ipi/Nivo➡️Surgery➡️Adj nivo in MSI-H
#GastricCancer & #EsophagealCancer
⏩32 pts
⏩59% path CR rate‼️
#TumorBoardTuesday #GI22

✅Also in the MSI-high group
➡️MA Lumish, et al "Rapid" Abs 16
⏩Neoadj dostarlimab (anti-PD-1) in localized dMMR #RectalCancer
⏩12 pts
➡️ORR = 100%

👉Small#⃣, and still very short follow up⏳
👉But VERY promising🙏
#TumorBoardTuesday #GI22

✅🗣️of Immuno💊
➡️A Nakata, et al Abs 346
⏩136 #GIcancer pts w/🧬profiling & also had Immuno💊(mostly gastric/esoph)
⏩7.4% w/SWI/SNF🧬muts
👉9 ARID1A/2 & 2 SMARCA4

👉mOS NR vs. 10.3 mos
👉ORR 30% vs. 12%
#TumorBoardTuesday #GI22


➡️E Tan et al Abs 663
⬆️OS in #GIcancer w/HRD🧬muts vs. no muts
⏩mOS 68.9 vs. 24.3mos
🤔No diff in ORR to plat💊❓

➡️S Amin et al Abs 599 & W Li et al Abs 601
🗣️Need to test for🧬muts in PDAC early
🔦NB: I am on these abstracts
#TumorBoardTuesday #GI22


➡️WW Ma et al Abs 563
⏩Rucaparib➕5FU/nal-iri Ph1
🤔Phase II in PDAC coming

➡️@aparna1024 et al Abs 564
⏩Niraparib➕antiPD-1 dostarlimab in PDAC
😞⛔️benefit in 15pts
💥BUT⛔️DDR pre-selection
🤔Would that have made a difference❓
#TumorBoardTuesday #GI22

✅Unless I missed it (and apologies if I did) I only saw one KRASG12C abstract
➡️@GIcancerDoc et al "RAPID" Abs 519
⏩KRYSTAL-1, adagrasib in #PancreaticCancer & other #GIcancers w/KRASG12C🧬muts
⏩27 eval pts – 41 % ORR‼️
👉50% in the PDAC pts👏
#TumorBoardTuesday #GI22

✅Finally, unfortunately there were two⛔️🎯💊 TAPUR trials

➡️GM Vaccaro et al Abs 107
⏩10 eval MSS #Colorectalcancer pts with
👉TMB >= 9
⏩Only 1 PR w/Ipi➕Nivo

➡️JL Grem et al Abs 106
⏩Temsirolimus in PIK3CA🧬mut #CRC
👉ORR=0% in 10 eval pts

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with #TumorBoardTuesday

#TumorBoardTuesday Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @TumorBoardTues

Jan 18
1/ 🌟 Calling #Oncology HCPs 🌟

🆕 #TumorBoardTuesday #Tweetorial #GI22
🧬 HER2 in Gastrointestinal Cancer
👥 @MPishvaian @BenWestphalen

Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.

CME ℹ️

⁉️ Your specialty
2/ 🗒️ Full reference list & glossary 👉

🔑 Key #CME & faculty info 👇, full info 👉

#TumorBoardTuesday #GI22 Image
3/ 🛑 POLL 🛑

🤔 How frequently do you currently employ emerging novel therapies & clinical trial enrollment for your patients ❓
#TumorBoardTuesday #GI22
Read 21 tweets
Dec 22, 2021
1/ 🌟 Calling #Oncology HCPs 🌟

🆕 #TumorBoardTuesday #Tweetorial
🚨 🧬 HER2 in Breast Cancer
👥 @MPishvaian & @ErikaHamilton9

Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.

CME ℹ️

🗣️ What's your specialty ⁉️
2/ 🗒️ Full reference list & glossary 👉

🔑 Key #CME & faculty info 👇, full info 👉

3/ 🛑 POLL 🛑

🤔 In a Ph3 trial, which agent has demonstrated an ORR of nearly 80% ❓
Read 24 tweets
Dec 17, 2021
1/9 #TumorBoardTuesday #PostTest Q1️⃣ #CME

@doctorC369 took us on a 🛣️through metastatic #GEA. Lots of pearls🦪 here. First: two ❓...then the wrap up!

🤔These biomarkers are actionable in advanced #EsophagoGastricCancer except…

👉🏽Posttest 🔗:
2/9 #PostTest Q2️⃣ #CME #TumorBoardTuesday


🤔 Addition of immunotherapy to chemotherapy in the 1st line Rx of advanced #EsophagoGastricCancer significantly improves PFS and OS PDL1 CPS>1%
3/9 #TumorBoardTuesday
Thursday Case🎀- 12.14.2021

Lots of take🏠messages- 2 TWEETS!
We discussed metastatic #GEA
✅Chemo + XRT needed to be used fast when facing obstruction- biomarkers can wait
📣✅REMEMBER- no 5-FU bolus‼️📣
Read 10 tweets
Dec 8, 2021
1/ 🗣️ #TumorBoardTuesday #Tweetorial

🧠 Prevalence, role, genomic testing 🧬HER family receptors
🥼 @MPishvaian @PancPathologist
Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichii Sankyo, Inc.

🆓 #CME 👉

📊 Your specialty👇 ❓
2/ 🗒️ Full reference list & glossary 👉

🔑 Key #CME & faculty info 👇 , full info 👉

#TumorBoardTuesday Image
3/ 🧬 HER2 alteration occurs in multiple cancer types

🔎 Breast cancer (BC) ➡️ 25% of cases

🔎 Gastric cancer (GC) ➡️ 22%

🔎 Gastroesophageal junction (GEJxn) cancer ➡️ 32%

🔎 Colorectal cancer (CRC) ➡️ 5%

🔎 Non-small cell lung cancer (NSCLC) ➡️ 6%-30%
#TumorBoardTuesday Image
Read 19 tweets
Dec 1, 2021
#TBTWebinar w/ @MPishvaian, @PancPathologist, @BreastCancerMD1, & Emanuel Petricoin

Claim credit

Supported by AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.…
HER2 #TBTWebinar 🔑

HER2 (ERBB2) is frequently altered in cancer
(Breast, Lung, Gastric, Biliary, CRC)

Marked by⬆️expression from🧬amplification

Also⬆️activity due to a🌟constitutively active🧬mutation

🤔1⃣of a few🎯molecular drivers of aggressive cancer Slide labels for alt text: ...
HER2 #TBTWebinar 🧐

➡️HER2 (ERBB2) testing & cut-offs varies between disease types

➡️IHC, FISH/CISH, & NGS can be used

➡️🧐Importantly, even HER2-low expression tumors may still benefit from emerging HER2-targeted antibody-drug conjugates🎯 Slide labels for alt text: ...
Read 7 tweets
Nov 12, 2021
1/8 #TumorBoardTuesday
➡️This week's Thurs Case🎀 is here!

🔬We discussed locally advanced #PancreaticCancer--& sig of germline muts (ATM). @SirohiBhawna takes us on her pt’s treatment journey.

🗝️insights 🤔on locally advanced #PANCAN below!
#PancreaticCancerAwarenessMonth Image
1.5/8 #TumorBoardTuesday

👉👉 Don’t forget to pick up your 🆓 #CME credit by answering 2 quick❓
Here’s the post-test 🔗:

ALL CME 🔗: Now...on to the case!
2/8 #TumorBoardTuesday
Thurs Case🎀

✅Upfront tx depends on pt- mFFX vs gem/nab-pac
✅Test all #PDAC for germline mut regardless of FH!‼️
✅Screen w annual MRI/EUS in gATM
✅Emerging 💊combos tx ATM-mut
#PANCAN req multi-D- role for palliative SBRT, ?IRE
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!